Keyword: Boehringer Ingelheim
News
18.07.2019
- Germany’s Boehringer Ingelheim has purchased AMAL Therapeutics for an undisclosed sum. AMAL is a private Swiss biotech that is focused on cancer immunotherapy and vaccines derived...
News
17.06.2019
- German drugmaker Boehringer Ingelheim and Danish biotech Gubra have announced a second collaboration and license agreement to develop novel poly-agonist peptides to treat obesity...
News
28.05.2019
- German drugmaker Boehringer Ingelheim is planning to invest around 1.6 billion pesos (about $84 million) at its three manufacturing sites in Mexico over the next two years, with...
News
10.05.2019
- The US market watchdog Public Citizen has sued the Food and Drug Administration (FDA), demanding that a district court in Washington, DC, require the agency to add “black box”...
News
06.12.2018
- Japan’s AGC, formerly Asahi Glass Co., has agreed to buy Malgrat Pharma Chemicals (MPC), a Spanish subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical...
News
12.11.2018
- Germany’s Boehringer Ingelheim has opened a new US biopharmaceutical manufacturing facility at Fremont, California, expanding its worldwide bioreactor capacity to 290,000 liters...
News
25.09.2018
- Boehringer Ingelheim has taken an option to buy all the shares of ViraTherapeutics, an Austrian biopharma that specializes in developing immunotherapy drugs based on oncolytic...
News
03.09.2018
- Boehringer Ingelheim has broken ground for a new €85 million facility at its headquarters in Ingelheim, Germany. The Solids Launch plant, slated to start up in 2020 and employ 75...
